Next Article in Journal
Outcomes of Universal Newborn Screening Programs: Systematic Review
Next Article in Special Issue
MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Previous Article in Journal
Role of Non-Invasive Respiratory Supports in COVID-19 Acute Respiratory Failure Patients with Do Not Intubate Orders
Previous Article in Special Issue
The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
Review

Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies

1
Clinical Hospital Center “Dr Dragisa Misovic-Dedinje”, Department of Hematology, University of Belgrade, 11000 Belgrade, Serbia
2
Molecular Oncology Group, Institute for Medical Research, University of Belgrade, 11000 Belgrade, Serbia
3
Centro Integrativo de Biología y Química Aplicada (CIBQA), Universidad Bernardo O’Higgins, 8370993 Santiago, Chile
*
Author to whom correspondence should be addressed.
Academic Editor: Helen A. Papadaki
J. Clin. Med. 2021, 10(13), 2788; https://doi.org/10.3390/jcm10132788
Received: 25 April 2021 / Revised: 14 June 2021 / Accepted: 21 June 2021 / Published: 24 June 2021
(This article belongs to the Special Issue Myeloid-Derived Suppressor Cells (MDSCs) in Haematology)
Myeloid malignancies arise from an altered hematopoietic stem cell and mainly comprise acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid neoplastic leukemic cells may influence the growth and differentiation of other hematopoietic cell lineages in peripheral blood and bone marrow. Myeloid-derived suppressor cells (MDSCs) and mesenchymal stromal cells (MSCs) display immunoregulatory properties by controlling the innate and adaptive immune systems that may induce a tolerant and supportive microenvironment for neoplasm development. This review analyzes the main features of MDSCs and MSCs in myeloid malignancies. The number of MDSCs is elevated in myeloid malignancies exhibiting high immunosuppressive capacities, whereas MSCs, in addition to their immunosuppression contribution, regulate myeloid leukemia cell proliferation, apoptosis, and chemotherapy resistance. Moreover, MSCs may promote MDSC expansion, which may mutually contribute to the creation of an immuno-tolerant neoplasm microenvironment. Understanding the implication of MDSCs and MSCs in myeloid malignancies may favor their potential use in immunotherapeutic strategies. View Full-Text
Keywords: myeloid malignancies/neoplasm; myeloid-derived suppressor cells; mesenchymal stem/stromal cells; T-cell immunosuppression; immunotherapy myeloid malignancies/neoplasm; myeloid-derived suppressor cells; mesenchymal stem/stromal cells; T-cell immunosuppression; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Kapor, S.; Santibanez, J.F. Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. J. Clin. Med. 2021, 10, 2788. https://doi.org/10.3390/jcm10132788

AMA Style

Kapor S, Santibanez JF. Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. Journal of Clinical Medicine. 2021; 10(13):2788. https://doi.org/10.3390/jcm10132788

Chicago/Turabian Style

Kapor, Suncica, and Juan F. Santibanez. 2021. "Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies" Journal of Clinical Medicine 10, no. 13: 2788. https://doi.org/10.3390/jcm10132788

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop